Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Businesswire News Releases

Jun 02, 2024 07:00 ET
June Joy at Juicy Stakes Casino
You know the drill. New month, same old Juicy Stakes Casino – bringing you a scorching set of specials with summer now firmly in sight....
Jun 01, 2024 14:25 ET
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program. Presentations include data informing clinical strategies for switching patients to UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults, from a once-monthly intramuscular injection of Invega Sustenna. The results were presented at the Psych Congress Elevate 2024 Annual M...
Jun 01, 2024 14:20 ET
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, reinforcing that TD has a wide-reaching, multidimensional impact on patients’ quality of life. These interim findings from the IMPACT-TD study were presented at the 2024 Psych Congress Elevate Annual Meeting, taking place from May 30 – June 2 in Las Vegas, Nevada....
Jun 01, 2024 10:00 ET
First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its AI-Enhanced Functional Precision Medicine Platform at ASCO 2024
First Ascent Biomedical announced findings from ongoing clinical studies conducted in partnership with Florida International University, examining the company’s Functional Precision Medicine (FPM) platform in adult and pediatric patients with difficult-to-treat cancers. The study findings were presented during poster sessions at the 2024 American Society of Clinical Oncology (ASCO) annual meeting in Chicago....
Jun 01, 2024 09:30 ET
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). The...
Jun 01, 2024 09:15 ET
Postmedia Announces Closing of Previously Announced Transaction with the Klein Group
Postmedia Network Inc., a wholly owned subsidiary of Postmedia Network Canada Corp. (“Postmedia” or “the Company”) today announced that it has closed its previously announced sale of the Winnipeg Sun, The Graphic Leader, Kenora Miner & News and the Winnipeg Press Commercial Print division to the Klein Group Ltd. (the “Klein Group”)....
Jun 01, 2024 09:00 ET
Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
Ankyra Therapeutics, a clinical-stage oncology company developing anchored immunotherapies to improve the therapeutic window for immuno-oncology drugs, announced today that it is presenting a Trial in Progress poster for the phase 1 ANCHOR clinical trial at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4, 2024 in Chicago, IL....
Jun 01, 2024 09:00 ET
Sally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ Community
Since 2019, Sally Hansen® has committed to partnering with GLAAD to support Pride and the organization’s mission to accelerate acceptance for the LGBTQ+ community. In the spirit of Pride 2024, this year’s NEW Sally Hansen® x Pride Limited-Edition Collection includes 11 metallic shades of the Progress Pride flag and 3 Salon Effects® Perfect Manicure designs modeled after the Trans, Bi, and Progress Pride flag!...
Jun 01, 2024 08:00 ET
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, announced data from an ongoing Phase 1 study of AC699 monotherapy in patients with ER-positive / HER2-negative locally advanced or metastatic breast cancer. The data will be presented in a poster discussion session at ...
Jun 01, 2024 08:00 ET
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced longer-term efficacy and safety results from Arm A1 of the Phase 2 EDGE-Gastric study. These updated data show consistent objective response rate (ORR) and provide mature progression-free survival (PFS) in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma (upper GI cancers). The ongoing, multi-arm, global Phase 2 EDGE-Gastric study is evaluating the safety and efficacy of various combinations of the Fc-silent anti-TIGIT antibody d...
Jun 01, 2024 08:00 ET
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, “Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial.” The publication is based on the results of HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso, Inc. (Akeso, HKEX Code: 9926.HK), with data generated and analyzed by Akeso....
Jun 01, 2024 08:00 ET
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Canc
Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 KRYSTAL-12 study evaluating KRAZATI® (adagrasib) compared to standard of care chemotherapy in patients with locally advanced or metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) who had previously received platinum-based chem...
Jun 01, 2024 08:00 ET
Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
ASCO Annual Meeting – Massive Bio, pioneering leader in AI-driven oncology solutions, is excited to announce the launch of its latest product, Drug Utilization Optimizer (DUO), at the upcoming ASCO Annual Meeting 2024. The innovative analytics and real-time notification platform is designed to revolutionize how pharmaceutical commercial teams tar...
Jun 01, 2024 08:00 ET
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study showed that the ADCETRIS combination reduced patients’ risk of death by 37% compared to placebo in combination with lenalidomide and rituximab (HR 0.63 [95% CI: 0.445-0.891] p=0.0085). The overall survival benefit was consistent across levels of CD30 expression....
May 31, 2024 22:02 ET
The Chemours Company Temporarily Pauses Titanium Dioxide Production at Altamira, Mexico Site Amid Severe Regional Drought
As a result of the severe drought impacting much of Mexico, The Chemours Company (“Chemours”) (NYSE: CC), a global chemistry company, today announced it is complying with a request from the government to temporarily minimize water intake, which has led to a pause in production at its Altamira Titanium Dioxide (TiO2) manufacturing facility to conserve water for the surrounding communities....
May 31, 2024 19:43 ET
Inocras Presents Poster for Breast Cancer at 2024 ASCO Annual Meeting, Showing Transformative Impact of WGS-based HRD Testing
Inocras Inc., a leader in whole genome sequencing (WGS) diagnostics and precision medicine, is proud to present groundbreaking research on radiogenomics and homologous recombination deficiency (HRD) in breast cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting....
May 31, 2024 18:00 ET
Capstone Copper Announces Retirement of Robert Gallagher from the Board of Directors
Capstone Copper Corp. (“Capstone” or the “Company”) (TSX:CS) (ASX:CSC) announces that Mr. Robert (“Bob”) Gallagher has retired from the Board of Directors of the Company effective May 30, 2024....